CA-125 vs. HE4: Why a Combined Approach May Be More Reliable
When it comes to ovarian health screening, understanding the difference between CA-125 and HE4 biomarkers — and why a combined approach may offer a more reliable picture — is increasingly important for women taking a proactive role in their wellbeing.
At Health Screening Clinic, our nurse-led team in London provides blood testing and reporting to help individuals gain clearer insight into their health. In this article, we explain what each biomarker measures, how they differ, and why combining CA-125 and HE4 is widely regarded as a more informative cancer screening strategy.
What Are CA-125 and HE4? A Quick Definition
CA-125 (Cancer Antigen 125) is a protein biomarker found in the blood. Elevated levels can sometimes be associated with ovarian conditions, though levels may also rise due to benign causes such as endometriosis, fibroids, menstruation, or pelvic inflammatory disease.
HE4 (Human Epididymis Protein 4) is a newer biomarker that can also be measured through a simple blood test. HE4 tends to be more specific to certain ovarian changes and is less likely to be elevated by the common benign conditions that often affect CA-125 results.
Snippet Definition: CA-125 and HE4 are blood-based protein biomarkers used in ovarian health screening. When measured together, they may provide a more reliable assessment than either marker alone, helping to reduce both false positives and false negatives in the screening process.
How Do CA-125 and HE4 Differ?
| Feature | CA-125 | HE4 |
|---|---|---|
| Type | Glycoprotein biomarker | Protease inhibitor biomarker |
| Specificity for ovarian concerns | Moderate — can be elevated by many benign conditions | Higher — less affected by common benign causes |
| Affected by menstruation | Yes | No |
| Affected by endometriosis | Yes — often significantly | Minimally |
| Age-related variability | More variable in premenopausal women | More consistent across age groups |
| Use in ROMA score | Yes — combined with HE4 | Yes — combined with CA-125 |
Practical Insight: For premenopausal women in particular, CA-125 alone can sometimes produce elevated readings that may not reflect genuine ovarian concerns. HE4 can help provide additional context in these situations.
Why May a Combined CA-125 and HE4 Approach Be More Reliable?
The concept behind combining these two biomarkers is straightforward: each marker compensates for the other's limitations. CA-125 has been used in clinical settings for decades and remains a valuable screening tool. However, its tendency to rise in response to various benign conditions means that an elevated result does not always point to a significant concern.
When both markers are assessed together, the combined data may:
- Reduce the rate of false-positive results compared to CA-125 alone
- Improve overall screening sensitivity by capturing a broader range of biomarker changes
- Support the calculation of the ROMA score, which takes both markers plus menopausal status into account
- Offer a more balanced and nuanced picture of ovarian health
- Provide additional context for healthcare professionals reviewing results
What Is the ROMA Score?
The ROMA (Risk of Ovarian Malignancy Algorithm) is a calculation that uses CA-125 levels, HE4 levels, and menopausal status to generate a risk stratification score. It is designed to help categorise individuals into lower or higher risk groups, which can then guide further clinical decision-making.
Practical Insight: If your results include a ROMA score, it is advisable to discuss the findings with a qualified healthcare professional who can interpret them within the context of your overall health history.
Who Should Consider CA-125 and HE4 Testing?
Ovarian health screening with a combined CA-125 and HE4 panel may be worth considering for:
- Women with a family history of ovarian or breast conditions
- Women over 50, particularly those who are postmenopausal
- Women experiencing persistent, unexplained symptoms such as bloating, pelvic discomfort, changes in appetite, or urinary frequency
- Women who carry known genetic factors (such as BRCA1 or BRCA2 variations)
- Anyone seeking a broader overview of their wellbeing as part of a proactive health screening approach
If you're exploring options for women's health blood tests, our clinic offers a range of panels designed to support proactive wellbeing monitoring.
How Often Should You Have CA-125 and HE4 Testing?
- For those with no specific risk factors, periodic screening as part of an annual or biannual health check may be appropriate
- For those with a family history or known genetic factors, more frequent monitoring — potentially every 6 to 12 months — may be discussed with a healthcare professional
- For those with previously elevated results, follow-up testing at intervals recommended by a qualified clinician can help track changes over time
Practical Insight: Establishing a baseline through initial testing can be particularly valuable. It allows future results to be compared against your own personal reference point, rather than relying solely on population-based reference ranges.
What Do Your Results Mean?
- Results within the normal reference range generally suggest that no significant elevation has been detected at the time of testing
- Mildly elevated results can sometimes reflect benign conditions, hormonal fluctuations, or other non-concerning factors
- Significantly elevated results may indicate that further discussion with an appropriate healthcare professional is advisable
Frequently Asked Questions
What is the difference between CA-125 and HE4?
CA-125 and HE4 are both blood-based protein biomarkers associated with ovarian health. CA-125 can be elevated by many benign conditions, whereas HE4 tends to be more specific and less affected by common non-ovarian causes, making them complementary when used together.
Why may a combined approach be more reliable than CA-125 alone?
Combining CA-125 and HE4 may reduce false-positive results and improve overall screening accuracy. HE4 compensates for CA-125's tendency to rise due to benign causes, while CA-125 can detect changes that HE4 alone might not flag.
What is the ROMA score and how is it calculated?
The ROMA score is a risk stratification algorithm that combines CA-125 levels, HE4 levels, and menopausal status. It helps categorise individuals into risk groups and may guide further clinical decision-making when interpreted by a healthcare professional.
Can CA-125 be elevated for reasons other than ovarian concerns?
Yes. CA-125 levels can sometimes rise due to endometriosis, fibroids, menstruation, pregnancy, pelvic inflammatory disease, and other benign conditions.
Can I get CA-125 and HE4 testing without a GP referral in the UK?
Yes. Private health screening clinics, such as Health Screening Clinic in London, offer CA-125 and HE4 blood testing without requiring a GP referral.
Disclaimer
This article is provided for educational and informational purposes only. The content is not intended to replace professional medical advice, diagnosis, or treatment. Individual symptoms, health concerns, or blood test results should always be assessed by an appropriately qualified healthcare professional. Health Screening Clinic provides testing and reporting services only and does not offer diagnosis, treatment, or prescriptions. No guarantees regarding health outcomes are made or implied.
